

CITATION REPORT

List of articles citing

Imiquimod applied topically: a novel immune response modifier and new class of drug

DOI: 10.1016/s0192-0561(98)00068-x

International Journal of Immunopharmacology, 1999,
21, 1-14.

Source: <https://exaly.com/paper-pdf/30358349/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
321	Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. 1999 , 44, 31-42		47
320	Treatment of warts. 2000 , 13, 290-304		7
319	Treatment of external genital warts. 2000 , 4, 128-34		
318	The management and prevention of premalignant penile lesions. 2000 , 220-9		13
317	Perspectives in dermatology: dermatologic oncology. 2000 , 11, s3-s8		
316	Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. 2000 , 44, 1869-73		30
315	European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. 2000 , 76, 162-8		145
314	Immune-response modifiers: a new paradigm in the treatment of human papillomavirus. 2000 , 61, 584-596		10
313	Recent advances in diagnosis and therapy of human papillomaviruses. 2000 , 9, 1753-65		4
312	Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation. 2001 , 55, 445-51		16
311	Fighting infection using immunomodulatory agents. 2001 , 1, 641-53		40
310	Immunologic approach to herpes simplex virus. 2001 , 14, 111-8		16
309	Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment. 2002 , 10, 79-88		27
308	Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. 2001 , 12, 22-28		55
307	Neuroimmune alterations in the complex regional pain syndrome. 2001 , 429, 101-13		45
306	Emerging therapies for human papillomavirus infection. 2001 , 6, 199-207		5
305	Successful treatment of perianal warts in a child with 5% imiquimod cream. 2001 , 12, 215-7		16

304	European guideline for the management of anogenital warts. 2001 , 12 Suppl 3, 40-7	46
303	Novel treatments for recurrent respiratory papillomatosis. 2002 , 11, 1139-48	6
302	Modulation of Th1 and Th2 responses for immunotherapy. 2002 , 12, 341-367	8
301	Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. 2002 , 195, 1507-12	393
300	Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream. 2002 , 347, 374	30
299	Imiquimod: A Review. 2002 , 6, 554-560	24
298	Leishmania Infection and Macrophage Function. 2002 , 105-113	2
297	Molluscum contagiosum: recent advances in pathogenic mechanisms, and new therapies. 2002 , 3, 535-45	52
296	Treatment of molluscum contagiosum with imiquimod 5% cream. 2002 , 47, S221-4	32
295	Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. 2002 , 47, S225-8	48
294	An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. 2002 , 47, S240-8	25
293	Immunomodulation as a treatment strategy for genital herpes: review of the evidence. 2002 , 2, 443-51	41
292	Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. 2002 , 63, 1120-5	51
291	Imiquimod. Un medicamento del siglo XXI. 2002 , 17, 285-291	1
290	Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. 2002 , 218, 74-86	328
289	Imiquimod: a potential role in dermatology?. 2002 , 147, 1-6	42
288	Discovery of immunopotentiatory drugs: current and future strategies. 2002 , 130, 363-9	24
287	Imiquimod 5% cream is an acceptable treatment option for external anogenital warts in uncircumcised males. 2002 , 16, 58-62	9

286	Imiquimod; an international update on therapeutic uses in dermatology. 2002 , 41, 810-6	41
285	Topische Immunmodulation in der Dermatologie. 2002 , 77, 116-130	
284	Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation. 2002 , 178, 175-82	13
283	Imiquimod 5% cream: a topical immune response modifier. 2002 , 41 Suppl 1, 1-2	12
282	Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. 2002 , 41 Suppl 1, 3-6	24
281	Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology. 2002 , 41 Suppl 1, 7-11	22
280	Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. 2002 , 3, 196-200	2003
279	Ethical considerations in psychopharmacological research involving decisionally impaired subjects. 2003 , 171, 92-7	20
278	The plasmacytoid monocyte/interferon producing cells. 2003 , 443, 703-17	117
277	Malignant conversion of florid oral and labial papillomatosis during topical immunotherapy with imiquimod. 2003 , 192, 161-4	7
276	The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. 2003 , 149 Suppl 66, 53-6	99
275	Viral warts in organ transplant recipients: new aspects in therapy. 2003 , 149 Suppl 66, 20-4	51
274	Imiquimod: modes of action. 2003 , 149 Suppl 66, 5-8	95
273	Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. 2003 , 149 Suppl 66, 9-14	62
272	Noninvasive imaging, treatment, and microscopic confirmation of clearance of basal cell carcinoma. 2003 , 29, 205-10	50
271	Immunotherapy of basal cell carcinoma: evolving approaches. 2003 , 29, 1027-34	30
270	Successful treatment of multiple filiform facial warts with imiquimod 5% cream in a patient infected by human immunodeficiency virus. 2003 , 28, 260-1	10
269	A review of imiquimod 5% cream for the treatment of various dermatological conditions. 2003 , 28 Suppl 1, 1-3	10

268	Recognition of pathogen-associated molecular patterns by TLR family. 2003 , 85, 85-95	890
267	The imidazoquinolines and their place in the therapy of cutaneous disease. 2003 , 4, 1105-19	21
266	Natural products and synthetic compounds as immunomodulators. 2003 , 1, 319-35	42
265	The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells. 2003 , 171, 1156-63	83
264	Myeloid differentiation factor 88-dependent and -independent pathways in toll-like receptor signaling. 2003 , 187 Suppl 2, S356-63	116
263	Noninvasive Imaging, Treatment, and Microscopic Confirmation of Clearance of Basal Cell Carcinoma. 2003 , 29, 205-210	23
262	New therapies for the management of keloids. 2003 , 14, 654-7	43
261	Immunotherapy of Basal Cell Carcinoma. 2003 , 29, 1027-1034	8
260	Imiquimod as a dermatological therapy. 2004 , 5, 427-38	22
259	Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. 2004 , 173, 3051-61	169
258	Therapy of cutaneous human Papillomavirus infections. 2004 , 17, 441-8	66
257	Imiquimod: potential risk of an immunostimulant. 2004 , 45, 123-4	34
256	Gene expression in actinic keratoses: pharmacological modulation by imiquimod. 2004 , 151, 1150-9	28
255	Topical imiquimod immunotherapy in the management of lentigo maligna. 2004 , 29, 15-21	76
254	New treatments for cutaneous human papillomavirus infection. 2004 , 18, 262-4	5
253	Two cases of squamous cell carcinoma treated with topical imiquimod 5%. 2004 , 18, 93-5	24
252	Safety and efficacy of locally applied imiquimod cream 5% for the treatment of condylomata acuminata of the vulva. 2004 , 270, 240-3	4
251	Current and novel treatment options for actinic keratosis. 2004 , 8 Suppl 3, 13-21	29

250	Role of topical therapies in the management of cutaneous disease. 2004 , 8 Suppl 3, 22-31	8
249	Viral and nonviral uses of imiquimod: a review. 2004 , 8, 338-52	71
248	Imiquimod contact pemphigus: a comment. 2004 , 115, 242-3	5
247	Infections [papillomavirus. 2004 , 1, 235-261	2
246	Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. 2004 , 22, 1799-809	80
245	Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. 2004 , 22, 1791-8	52
244	Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. 2004 , 50, 792-6	36
243	Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. 2004 , 50, 722-33	390
242	Infections [papillomavirus. 2004 , 1, 1-19	3
241	Viral and Nonviral Uses of Imiquimod: A Review. 2004 , 8, 338-352	61
240	Bowen's disease involving the urethra. 2005 , 32, 210-3	5
239	Current and potential uses of imiquimod. 2005 , 98, 914-20	52
238	Treatment of multiple lesions of Bowen's disease and squamous cell carcinoma with topical imiquimod. 2005 , 32, 1005-9	6
237	A case of eccrine poroma treated with 5% imiquimod cream. 2005 , 32, 691-3	4
236	Infiltrative trichilemmal carcinoma treated with 5% imiquimod cream. 2005 , 31, 973-6	11
235	Discovery of novel immunostimulants by dendritic-cell-based functional screening. 2005 , 106, 3082-9	48
234	Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. 2005 , 106, 2424-32	89
233	Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina?. 2005 , 15, 898-902	36

232	Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine. 2005 , 16, 338-45	41
231	Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. 2005 , 44, 14-9	62
230	Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. 2005 , 44, 428-34	46
229	Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. 2005 , 152, 939-47	187
228	Mechanisms of innate immune responses mediated by Toll-like receptors. 2005 , 5, 167-183	5
227	Anal intraepithelial neoplasia. 2005 , 92, 277-90	107
226	Amelioration of Acute Renal Failure by Stem Cell Therapy Paracrine Secretion Versus Transdifferentiation into Resident Cells. 2005 , 16, 1153-1163	12
225	The management of non-melanoma skin cancer. 2005 , 66, 288-93	2
224	Genital warts: current and future management options. 2005 , 6, 239-43	28
223	Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. 2005 , 140, 1136-9	34
222	Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. 2005 , 48, 3481-91	93
221	Novel methods to treat and prevent human papillomavirus infection. 2006 , 4, 593-600	2
220	Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. 2006 , 18, 1115-26	126
219	Immune response modifiers: Imiquimod and future drugs for modulating the immune response. 2006 , 3, 343-352	2
218	Updates in therapeutics for veterinary dermatology. 2006 , 36, 39-58, vi	8
217	Wound healing: an overview. 2006 , 117, 1e-S-32e-S	377
216	Eruptive Epidermoid Cysts Resulting from Treatment with Imiquimod. 2006 , 31, 780-784	3
215	Infiltrative Trichilemmal Carcinoma Treated with 5% Imiquimod Cream. 2006 , 31, 973-976	4

214	Permanent facial hypopigmentation following treatment with imiquimod cream. 2006 , 31, 721-2	15
213	Apoptotic responses in squamous carcinoma and epithelial cells to small-molecule toll-like receptor agonists evaluated with automated cytometry. 2006 , 11, 575-85	14
212	Proceedings From the First Asia-Oceania Research Organisation on Genital Infections and Neoplasia (AOGIN) Meeting. 2006 , 2006, 1-38	78
211	Efficacy of an immune modulator in experimental Chlamydia trachomatis infection of the female genital tract. 2006 , 2006, 61265	
210	Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer. 2007 , 8, 1743-55	26
209	Topical immunomodulation: modes of action with clinical correlation. 2007 , 25, 147-55, vi	2
208	Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. 2007 , 5, 7	41
207	Experimental and theoretical study on the structure and electronic spectra of imiquimod and its synthetic intermediates. 2007 , 17, 4942-6	10
206	Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod. 2007 , 157, 1132-47	19
205	A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. 2007 , 157 Suppl 2, 34-40	200
204	Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. 2007 , 8, 26	62
203	Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. 2007 , 73, 1-11	66
202	Contact pemphigus: a side-effect of imiquimod therapy. 2008 , 47, 765-7	15
201	Confocal microscopy: innovative diagnostic tools for monitoring of noninvasive therapy in cutaneous malignancies. 2008 , 5, e81-e91	13
200	Imidazoquinoline acts as immune adjuvant for functional alteration of thymic stromal lymphopoietin-mediated allergic T cell response. 2008 , 181, 5340-9	19
199	Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects. 2008 , 201-20	12
198	Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. 2008 , 19, 159-63	36
197	Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. 2008 , 233, 968-79	46

196	A Review of Topical Imiquimod in the Management of Basal Cell Carcinoma, Actinic Keratoses, and Other Skin Lesions. 2009 , 1, CMT.S1969	
195	A case of erythroplasia of queyrat treated with imiquimod 5% cream and excision. 2009 , 21, 419-22	16
194	A study on the use of imiquimod for the treatment of genital molluscum contagiosum and genital warts in female patients. 2009 , 30, 84-8	9
193	Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS. 2009 , 32, 1363-73	10
192	Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. 2009 , 2 Suppl 1, 205-14	222
191	NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. 2009 , 58, 575-87	24
190	Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. 2009 , 161, 897-903	39
189	Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. 2009 , 35, 629-33	46
188	Topical treatment of bowenoid papulosis of the penis with imiquimod. 2009 , 23, 978-9	13
187	Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. 2009 , 23, 1061-5	54
186	Plasmacytoid dendritic cells in the skin: to sense or not to sense nucleic acids. 2009 , 21, 101-9	47
185	Angiogenesis in cutaneous disease: part I. 2009 , 61, 921-42; quiz 943-4	27
184	Imiquimod inhibits the differentiation but enhances the maturation of human monocyte-derived dendritic cells. 2009 , 9, 412-7	12
183	Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. 2010 , 59, 1573-82	192
182	Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. 2010 , 59, 1877-1884	51
181	Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp. 2010 , 302, 539-44	15
180	Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. 2010 , 17, 32	36
179	An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. 2010 , 23, 458-76	45

178	Current views of toll-like receptor signaling pathways. 2010 , 2010, 240365	137
177	Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors. 2010 , 235, 1292-9	7
176	Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. 2010 , 10, 1081-7	82
175	Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues. 2010 , 53, 4450-65	109
174	Emerging drugs for actinic keratosis. 2010 , 15, 545-55	18
173	More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. 2010 , 21, 8-16	42
172	4-Hydrazinyl-1-isobutyl-1H-imidazo[4,5-c]quinoline. 2011 , 67, o406	3
171	T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. 2011 , 216, 579-90	45
170	Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses. 2011 , 4, 35-40	7
169	Scarless Wound Healing. 2011 , 103-127	1
168	Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions. 2011 , 6, 428-440	9
167	Laser immunotherapy for treatment of patients with advanced breast cancer and melanoma. 2011 , 276, 012023	
166	Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells. 2011 , 117, 5683-91	28
165	Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. 2011 , 164, 670-2	74
164	Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis: a 12-month follow-up study. 2011 , 165, 888-92	26
163	Depigmentation therapies for normal skin in vitiligo universalis. 2011 , 25, 749-57	56
162	Role of TLR2-dependent inflammation in metastatic progression. 2011 , 1217, 191-206	48
161	[Conservative treatment of anogenital HPV infections]. 2011 , 62, 34-9	2

160	Nonsurgical treatment options for Basal cell carcinoma. 2011 , 2011, 571734	22
159	1-Isobutyl-4-meth-oxy-1H-imidazo[4,5-c]quinoline. 2011 , 67, o2331	
158	Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons. 2011 , 108, 3371-6	71
157	Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. 2012 , 72, 5240-9	193
156	1-{4-[(1-Isobutyl-1H-imidazo[4,5-c]quinolin-4yl)amino]phenyl}ethanone. 2012 , 2012, M788	3
155	Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling. 2012 , 17, 13503-29	48
154	Deciphering the message broadcast by tumor-infiltrating dendritic cells. 2012 , 181, 733-42	48
153	Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines. 2012 , 3, 749-60	40
152	[Oral acitretin and topical imiquimod as neoadjuvant treatment for giant basal cell carcinoma]. 2012 , 103, 149-52	5
151	Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity. 2012 , 1826, 407-14	5
150	Emerging human papillomavirus vaccines. 2012 , 17, 469-92	52
149	Oral Acitretin and Topical Imiquimod as Neoadjuvant Treatment for Giant Basal Cell Carcinoma. 2012 , 103, 149-152	
148	Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. 2012 , 18, 955-67	38
147	Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction. 2012 , 3, 501-504	28
146	Potential efficacy of imiquimod on immunity-related cytokines in murine skin in vivo and in human Langerhans cells in vitro. 2012 , 51, 1116-22	3
145	Imiquimod: The biochemical mechanisms of immunomodulatory and anti-inflammatory activity. 2013 , 7, 136-145	2
144	Efficacy of imiquimod 5% cream for persistent human papillomavirus in genital intraepithelial neoplasm. 2013 , 52, 475-8	13
143	Anti-herpes virus activities of <i>Achyranthes aspera</i> : an indian ethnomedicine, and its triterpene acid. 2013 , 168, 238-44	50

142	Mécanismes d'action de l'imiquimod et implication dans le traitement des affections cutanées virales humaines et animales. 2013 , 48, 105-112	1
141	Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients. 2013 , 40, 962-7	7
140	TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells. 2013 , 70, 317-26	7
139	In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod. 2013 , 42, 2087-93	25
138	Imiquimod for anogenital warts in non-immunocompromised adults. 2013 ,	2
137	Recommended Managements for the Male Human Papillomavirus Infection. 2014 , 9, 79	1
136	Imiquimod for anogenital warts in non-immunocompromised adults. 2014 , CD010389	26
135	Spanish adaptation of the European guidelines for the evaluation and treatment of actinic keratosis. 2014 , 105, 378-93	1
134	Synthesis of azabicyclo[4.2.0]octa-1,3,5-trien-8-one analogues of 1H-imidazo[4,5-c]quinoline and evaluation of their antimicrobial and anticancer activities. 2014 , 23, 2964-2975	11
133	Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model. 2014 , 87, 310-7	26
132	The activation of TLR7 regulates the expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells. 2014 , 389, 43-9	10
131	Adaptación española de la Guía europea para la evaluación y tratamiento de la queratosis actínica. 2014 , 105, 378-393	31
130	[Stimulating Type I interferon response with small molecules: revival of an old idea]. 2015 , 209, 145-59	1
129	Biodegradable Nanofiber for Delivery of Immunomodulating Agent in the Treatment of Basal Cell Carcinoma. 2015 , 3, 478-490	19
128	Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. 2015 , 6, 271	32
127	Principles of oncological therapy. 2015 , 118-197	2
126	IRF4, MC1R and TYR genes are risk factors for actinic keratosis independent of skin color. 2015 , 24, 3296-303	27
125	New antagonists of toll-like receptor 7 discovered through 3D ligand-based virtual screening. 2015 , 24, 362-371	11

124	Topical treatment of basal cell carcinoma with the immune response modifier imiquimod. 2015 , 11, 2985-90	11
123	In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. 2015 , 9, 1966-81	94
122	Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants. 2015 , 32, 311-20	25
121	Aldara [®] -induced skin inflammation: studies of patients with psoriasis. 2015 , 172, 345-53	38
120	Virtual Screening Approaches towards the Discovery of Toll-Like Receptor Modulators. 2016 , 17,	22
119	Identification of Adjuvant Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen. 2016 , 11, e0149848	33
118	Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccination for Cancer. 2016 , 129-162	
117	The effect of imiquimod on taste bud calcium transients and transmitter secretion. 2016 , 173, 3121-3133	4
116	MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice. 2016 , 39, 369-376	8
115	Mechanisms of imiquimod skin penetration. 2016 , 511, 516-523	26
114	Imiquimod in dermatology: an overview. 2016 , 55, 831-44	86
113	Plasmacytoid dendritic cell role in cutaneous malignancies. 2016 , 83, 3-9	23
112	Discovery of 6-Amino-2-[[[(1S)-1-methylbutyl]oxy]-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma. 2016 , 59, 1711-26	33
111	Paget disease of the vulva. 2016 , 101, 60-74	89
110	Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata. 2017 , 58, 219-223	7
109	[Eruptive epidermoid cysts during topical imiquimod treatment]. 2017 , 144, 212-215	1
108	Intralesional treatment of metastatic melanoma: a review of therapeutic options. 2017 , 66, 647-656	30
107	Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?. 2017 , 33, 193-202	3

106	The use of chitosan as cationic coating or gel vehicle for polymeric nanocapsules: Increasing penetration and adhesion of imiquimod in vaginal tissue. 2017 , 114, 202-212	60
105	Papillomaviruses in dogs and cats. 2017 , 225, 23-31	56
104	[Prevention and therapy of actinic keratoses]. 2017 , 159, 60-68	
103	Vaginal drug delivery for the localised treatment of cervical cancer. 2017 , 7, 817-828	22
102	Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination. 2017 , 77, 1-15	29
101	Plasmacytoid dendritic cells and type I interferon in the immunological response against warts. 2017 , 42, 857-862	13
100	Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B. 2017 , 60, 6137-6151	10
99	Toll-like receptors in mycobacterial infection. 2017 , 808, 1-7	15
98	Efficacy of 2 Representative Topical Agents to Prevent Keloid Recurrence After Surgical Excision. 2017 , 75, 401.e1-401.e6	13
97	Treating Scars to the Neck. 2017 , 25, 99-104	1
96	Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model. 2017 , 8, 3183-3189	6
95	Selective hemangioma cell dysfunction and apoptosis triggered by in vitro treatment with imiquimod. 2018 , 288, 82-88	4
94	Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells. 2018 , 328, 33-48	2
93	Anti-psoriatic and toxicity evaluation of methotrexate loaded chitin nanogel in imiquimod induced mice model. 2018 , 110, 245-258	32
92	EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica. 2018 , 12, e0006854	18
91	Current developments in pharmacotherapy for actinic keratosis. 2018 , 19, 1693-1704	5
90	Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma. 2018 , 23, 273-280	19
89	Photothermal-Activatable FeO Superparticle Nanodrug Carriers with PD-L1 Immune Checkpoint Blockade for Anti-metastatic Cancer Immunotherapy. 2018 , 10, 20342-20355	86

88	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. 2019 , 1-28	
87	Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds. 2019 , 179, 109-122	9
86	Vaginal Intraepithelial Neoplasia (VaIN): Diagnosis and Management. 2019 , 315-331	
85	The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline μ transcription through the induction of BCL6 expression in B cells. 2019 , 338, 1-8	7
84	Immune Responses Alter Taste Perceptions: Immunomodulatory Drugs Shape Taste Signals during Treatments. 2019 , 371, 684-691	1
83	Development and Validation of Stability Indicating UPLC-PDA/MS for the Determination of Imiquimod and its Eight Related Substances: Application to Topical Cream. 2019 , 57, 249-257	0
82	ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK/IL-17 signaling pathway. 2019 , 66, 236-241	13
81	Novel viruses: Update on the significance of papillomavirus infections in cats. 2019 , 21, 409-418	10
80	Anti-HPV Nanoemulsified-Imiquimod: A New and Potent Formulation to Treat Cervical Cancer. 2020 , 21, 54	6
79	Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines. 2020 , 30, 126788	4
78	Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 - 2020. 2020 , 30, 825-845	3
77	Detection of a Putative Novel Papillomavirus Type within a Large Exophytic Papilloma on the Fetlock of a Horse. 2020 , 9,	1
76	Effect of Imiquimod on Tachyzoites of and Infected Macrophages and in BALB/c Mice. 2020 , 10, 387	5
75	Photocarcinogenesis. 2020 , 9, 189-199	4
74	Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. 2020 , 63, 10188-10203	26
73	Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. 2020 , 188, 109858	39
72	Multi-stage surgery combined with radiotherapy for treatment of giant anterior chest wall keloid: A case report. 2020 , 99, e18886	1
71	Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. 2020 , 193, 112238	39

70	Characterization of bovine ileal epithelial cell line for lectin binding, susceptibility to enteric pathogens, and TLR mediated immune responses. 2021 , 74, 101581	2
69	Recent synthetic methodologies for the tricyclic fused-quinoline derivatives. 2021 , 51, 13-36	3
68	Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles. 2021 , 12, 1065-1120	6
67	TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection. 2020 , 11, 622614	24
66	Cancer Immunoprevention: Current Status and Future Directions. 2021 , 69, 3	4
65	Imiquimod Targets Toxoplasmosis Through Modulating Host Toll-Like Receptor-MyD88 Signaling. 2021 , 12, 629917	7
64	Safety of topical interventions for the treatment of actinic keratosis. 2021 , 20, 801-814	0
63	Topical Imiquimod for the Treatment of High-Grade Squamous Intraepithelial Lesions of the Cervix: A Randomized Controlled Trial. 2021 , 137, 1043-1053	4
62	Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors. 2021 , 64, 8010-8041	6
61	Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy. 2021 , 23, 90	3
60	Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. 2021 , 175, 113803	13
59	Papillomaviruses in Domestic Cats. 2021 , 13,	2
58	Improvement of Imiquimod Solubilization and Skin Retention via TPGS Micelles: Exploiting the Co-Solubilizing Effect of Oleic Acid. 2021 , 13,	1
57	Imiquimod Accelerated Antitumor Response by Targeting Lysosome Adaptation in Skin Cancer Cells. 2021 , 141, 2219-2228.e8	1
56	Scar Revision Review. 2012 , 14, 162-174	10
55	Actinic keratoses. 2009 , 146, 227-39	5
54	Local Melanoma Recurrence, Satellitosis, and In-transit Metastasis: Incidence, Outcomes, and Selection of Treatment Options. 2020 , 867-894	3
53	The toll-like receptor agonist imiquimod is active against prions. 2013 , 8, e72112	21

52	Immunomodulator-based enhancement of anti smallpox immune responses. 2015 , 10, e0123113	6
51	Treatment of Molluscum Contagiosum by Potassium Hydroxide Solution 20% with and Without Pricking and By Pricking Alone: A Comparative Study with Review of Literature. 031-041	5
50	[Imiquimod: the biochemical mechanisms of immunomodulatory and anti-inflammatory activity]. 2013 , 59, 249-66	4
49	Imiquimod inhibits the growth of SGC-7901 cells in vitro through induction of autophagy and apoptosis. 2016 , 13, 393-7	3
48	Successful Treatment of Giant Basal Cell Carcinoma with Topical Imiquimod 5% Cream with Long Term Follow-up. 2014 , 59, 575-8	10
47	Diagnosis and Treatment of Actinic Keratosis. 2010 , 25, 214-231	2
46	Immune therapy for human papillomaviruses-related cancers. 2014 , 5, 1002-19	36
45	Augmentation of Cell-Mediated Immunity to Virus. 2004 , 45-65	
44	Imiquimod: F1alles gut?. 2005 , 539-543	
43	Therapeutic Strategies Targeting the Innate Antiviral Immune Response. 2008 , 223-251	
42	Sexually transmitted diseases. 2010 , 718-742	
41	Squamous Cell Carcinoma In Situ. 2010 , 51-59	
40	Genitoanal HPV Infection and Associated Neoplasias in the Male. 2011 , 489-509	
39	Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. 2013 , 71-108	
38	: Topical and Intralesional Therapies. 2014 , 139-156	
37	Update on Benign and Inflammatory Skin Disease Secondary to Transplant Medication. 2015 , 1-17	
36	Imiquimod. 2015 , 1465-1471	
35	Human papillomavirus: local treatment of anogenital lesions. 2016 , 15, 102	0

34	Topical Immune Response Modifiers: Adjuvants. 2017 , 775-790		
33	Human papillomavirus infection: current understanding of the pathogenesis and treatment. 2018 , 17, 94		1
32	[CME: Update Actinic Keratoses]. 2019 , 108, 381-388		
31	Further Exploration of the SAR of Imidazoquinolines; Identification of Potent C7 Substituted Imidazoquinolines.		
30	Viral Diseases. 2020 , 359-385		
29	Modern concepts of human papillomavirus infection: epidemiology and treatment tactics of patients with ano-genital warts. 2020 , 19, 719		2
28	Toll-like receptors as pharmacological targets. 2006 , 223-240		
27	Topical Immune Response Modifiers: Adjuvants. 2008 , 527-537		
26	Topical imiquimod therapy for actinic keratosis: is long-term clearance a realistic benefit?. 2008 , 1, 44-7		2
25	Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream. 2011 , 4, 39-43		2
24	Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach. 2014 , 7, S2-S12		11
23	Optimizing dendritic cell-based approaches for cancer immunotherapy. 2014 , 87, 491-518		37
22	Apoptotic Effect of Morphine, Imiquimod and Nalmefene on Promastigote, Infected and Uninfected Macrophages with Amastigote of by Flow Cytometry. <i>Iranian Journal of Pharmaceutical Research</i> , 2018 , 17, 986-994	1.1	5
21	Evaluation of Morphine with Imiquimod as Opioid Growth Factor Receptor or Nalmefene as Opioid Blocking Drug on Leishmaniasis Caused by in Vitro. <i>Iranian Journal of Parasitology</i> , 2019 , 14, 394-403	0.8	4
20	Sexually Transmitted Infections of the Colon and Rectum. 2022 , 323-342		
19	Modern therapy of anogenital warts. <i>Vestnik Dermatologii I Venerologii</i> , 2015 , 91, 134-142	0.4	2
18	Toxoplasmosis: Current and Emerging Parasite Druggable Targets.. <i>Microorganisms</i> , 2021 , 9,	4.9	2
17	Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	2

16	Revisiting metallodrugs for the treatment of skin cancers. <i>Coordination Chemistry Reviews</i> , 2022 , 462, 214506	23.2	2
15	New Approach to create an Effective Natural Treatments of Infections caused by Human Papillomavirus. <i>Journal of Molecular Docking</i> , 2021 , 1, 68-77		
14	Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease.. <i>Chinese Medicine</i> , 2022 , 17, 53	4.7	2
13	Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell.. <i>European Respiratory Review</i> , 2022 , 31,	9.8	2
12	Papillomaviral skin diseases of humans, dogs, cats and horses: A comparative review. Part 1: Papillomavirus biology and hyperplastic lesions. 2022 , 288, 105897		1
11	Imiquimod cream improves photodamaged skin. 2022 , 26, 38		0
10	Imiquimod-induced ROS production causes lysosomal membrane permeabilization and activates caspase-8-mediated apoptosis in skin cancer cells. 2022 , 107, 142-150		0
9	A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma.		0
8	Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review. 2022 , 10, 1727		0
7	Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy. 2022 , 244, 114867		0
6	Antitumor Immunity Exerted by Natural Killer and Natural Killer T Cells in the Liver. 2023 , 12, 866		0
5	Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses. 14,		0
4	Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer. 2023 , 7,		1
3	Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. 2023 , 9,		0
2	Targeted therapy. 2023 , 205-411		0
1	Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment. 2023 , 14,		0